In another recent RCT in adult patients with biopsy-proven NAFLD, a reduction in liver fat content (assessed by magnetic resonance imaging proton density fat fraction (PDFF)) after 12 weeks of treatment with MGL-3196 (a selective TSH receptor ß agonist) was demonstrated [194]. The gene discussed is TSHR; the disease is metabolic dysfunction-associated steatotic liver disease.